Last updated on June 2019

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Brief description of study

The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G).

Detailed Study Description

C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). There is no approved treatment for patients with C3G.

This is a randomized, double blind, placebo controlled Phase 2 study to evaluate the safety and efficacy of avacopan (CCX168) in patients with C3G. The primary objective is to evaluate the efficacy of avacopan compared to placebo based on histologic changes in kidney biopsies taken before and during treatment.

Clinical Study Identifier: NCT03301467

Find a site near you

Start Over

Hospital of Miami

Miami, FL United States
  Connect »

Northwestern Medical Group

Chicago, IL United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

Mayo Clinic

Rochester, NY United States
  Connect »

St. Paul Hospital

Vancouver, BC Canada
  Connect »

Radboud UMC

Nijmegen, Netherlands
  Connect »

Royal London Hospital

London, United Kingdom
  Connect »

Freeman Hospital

Newcastle Upon Tyne, United Kingdom
  Connect »